The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study
Abstract
Objective: A high frequency of infections complicating rheumatoid arthritis (RA) has been described in reports of case series. This retrospective longitudinal cohort study was undertaken to compare the frequency of infections in a population‐based incidence cohort of RA patients with that in a group of individuals without RA from the same population. Methods: RA patients included all members of an incidence cohort of Rochester, Minnesota residents ages ≥18 years who were first diagnosed as having RA between 1955 and 1994. One age‐ and sex‐matched subject without RA was selected for each patient with RA. Study subjects were followed up by review of their entire medical record until death, migration from the area, or study end (January 1, 2000), and details of all documented infections, along with information on potential risk factors for infection, were recorded. Hazard ratios for infections were estimated using stratified Andersen‐Gill proportional hazards models, with adjustment for potential confounders. Results: The 609 RA patients and 609 non‐RA study subjects (mean age 58.0 years; 73.1% female) were followed up for a mean of 12.7 years and 15.0 years, respectively, reflecting higher mortality among the group with RA. Hazards ratios for objectively confirmed infections, infections requiring hospitalization, and any documented infection in patients with RA were 1.70 (95% confidence interval [95% CI] 1.42–2.03), 1.83 (95% CI 1.52–2.21), and 1.45 (95% CI 1.29–1.64), respectively, after adjustment for age, sex, smoking status, leukopenia, corticosteroid use, and diabetes mellitus. Sites of infection with the highest risk ratios were bone, joints, skin, soft tissues, and the respiratory tract. Conclusion: In this study, patients with RA were at increased risk of developing infections compared with non‐RA subjects. This may be due to immunomodulatory effects of RA, or to agents with immunosuppressive effects used in its treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
The Patient Record in Epidemiology
Kurland, L. T., & Molgaard, C. A. (1981) · Scientific American · doi:10.1038/scientificamerican1081-54 · Cited by 777
Saag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B., Kohler, J. A., & Furst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540
Doran, M. F., Pond, G. R., Crowson, C. S., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.509 · Cited by 469
Self-citationT cell homeostasis in patients with rheumatoid arthritis
Koetz, K., Bryl, E., Spickschen, K., O'Fallon, W. M., Goronzy, J. J., & Weyand, C. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.16.9203 · Cited by 467
Self-citationTen year mortality and causes of death in patients with rheumatoid arthritis.
Mutru, O., Laakso, M., Isomäki, H., & Koota, K. (1985) · BMJ · doi:10.1136/bmj.290.6484.1797 · Cited by 264
CAUSE OF DEATH IN RHEUMATOID ARTHRITIS
PRIOR, P., SYMMONS, D. P. M., SCOTT, D. L., BROWN, R., & HAWKINS, C. F. (1984) · Rheumatology · doi:10.1093/rheumatology/23.2.92 · Cited by 247
Cited by
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Gabriel, S. E., & Michaud, K. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2669 · Cited by 891
Self-citationDixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Galloway, J. B., Hyrich, K. L., Mercer, L. K., Dixon, W. G., Fu, B., Ustianowski, A. P., Watson, K. D., Lunt, M., BSRBR Control Centre Consortium, Symmons, D. P. M., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/keq242 · Cited by 676
van Assen, S., Agmon-Levin, N., Elkayam, O., Cervera, R., Doran, M. F., Dougados, M., Emery, P., Geborek, P., Ioannidis, J. P. A., Jayne, D. R. W., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137216 · Cited by 630
Self-citationNew Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Predictors of infection in rheumatoid arthritis
Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10529 · Cited by 560
Self-citationThe risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Infection Risk and Safety of Corticosteroid Use
Youssef, J., Novosad, S. A., & Winthrop, K. L. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.004 · Cited by 459
COVID-19 infection and rheumatoid arthritis: Faraway, so close
Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454
Kremer, J. M., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A.-M., Vernon, E., Ambs, P., & Fleischmann, R. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30158 · Cited by 409
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398
Schiff, M. H., Burmester, G. R., Kent, J. D., Pangan, A. L., Kupper, H., Fitzpatrick, S. B., & Donovan, C. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.043166 · Cited by 390
Bongartz, T., Halligan, C. S., Osmon, D. R., Reinalda, M. S., Bamlet, W. R., Crowson, C. S., Hanssen, A. D., & Matteson, E. L. (2008) · Arthritis Care & Research · doi:10.1002/art.24060 · Cited by 388
Self-citationIntegrated safety in tocilizumab clinical trials
Schiff, M. H., Kremer, J. M., Jahreis, A., Vernon, E., Isaacs, J. D., & van Vollenhoven, R. F. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3455 · Cited by 367
Rheumatoid arthritis-associated lung disease
Shaw, M., Collins, B. F., Ho, L. A., & Raghu, G. (2015) · European Respiratory Review · doi:10.1183/09059180.00008014 · Cited by 366
Grijalva, C. G., Chen, L., Delzell, E., Baddley, J. W., Beukelman, T., Winthrop, K. L., Griffin, M. R., Herrinton, L. J., Liu, L., Ouellet-Hellstrom, R., et al. (2011) · JAMA · doi:10.1001/jama.2011.1692 · Cited by 350
Strehl, C., Bijlsma, J. W. J., de Wit, M., Boers, M., Caeyers, N., Cutolo, M., Dasgupta, B., Dixon, W. G., Geenen, R., Huizinga, T. W. J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208916 · Cited by 340
Immune suppression and immune activation in depression
Blume, J., Douglas, S. D., & Evans, D. L. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.008 · Cited by 338
Au, K., Reed, G., Curtis, J. R., Kremer, J. M., Greenberg, J. D., Strand, V., & Furst, D. E. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.128637 · Cited by 337
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases
Perl, A. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 332
Ledingham, J., Deighton, C., & on behalf of the British Society for Rheumatology Standards, G. A. A. W. G. (2005) · Rheumatology · doi:10.1093/rheumatology/keh464 · Cited by 331
Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy
Tsiodras, S., Samonis, G., Boumpas, D. T., & Kontoyiannis, D. P. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60839-2 · Cited by 331
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy
Kroesen, S. (2003) · Rheumatology · doi:10.1093/rheumatology/keg263 · Cited by 328
Kapetanovic, M. C., Saxne, T., Sjöholm, A., Truedsson, L., Jönsson, G., & Geborek, P. (2006) · Rheumatology · doi:10.1093/rheumatology/kei193 · Cited by 319
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, R., Modafferi, D., Zhou, L., Bell, D., & Appleton, B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048371 · Cited by 305
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Hua, C., Barnetche, T., Combe, B., & Morel, J. (2014) · Arthritis Care & Research · doi:10.1002/acr.22246 · Cited by 287
Schneeweiss, S., Setoguchi, S., Weinblatt, M. E., Katz, J. N., Avorn, J., Sax, P. E., Levin, R., & Solomon, D. H. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22600 · Cited by 302
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Furst, D. E. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.10.002 · Cited by 291
Smitten, A. L., Choi, H. K., Hochberg, M. C., Suissa, S., Simon, T. A., Testa, M. A., & Chan, K. A. (2007) · Arthritis Care & Research · doi:10.1002/art.23112 · Cited by 281
Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
Bernatsky, S., Hudson, M., & Suissa, S. (2007) · Rheumatology · doi:10.1093/rheumatology/kem076 · Cited by 281
Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy
Alam, J., Jantan, I., & Bukhari, S. N. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.055 · Cited by 280
Greenberg, J. D., Reed, G., Kremer, J. M., Tindall, E., Kavanaugh, A., Zheng, C., Bishai, W., & Hochberg, M. C. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.089276 · Cited by 275
Clinical Features of Rheumatoid Arthritis
Harris, E. D., & Firestein, G. S. (2009) · Kelley's Textbook of Rheumatology · doi:10.1016/b978-1-4160-3285-4.10066-x · Cited by 275
Flendrie, M., Vissers, W. H., Creemers, M. C., de Jong, E. M., van de Kerkhof, P. C., & van Riel, P. L. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1724 · Cited by 259
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., Chen, L., Dickson, C. L., Riddle Camp, J., Cardillo, T. E., et al. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.171361 · Cited by 258
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
Raison, C. L., & Miller, A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.2 · Cited by 253
EL-GABALAWY, H., GUENTHER, L. C., & BERNSTEIN, C. N. (2010) · The Journal of Rheumatology Supplement · doi:10.3899/jrheum.091461 · Cited by 253
Vallejo, A. N., Weyand, C. M., & Goronzy, J. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.002 · Cited by 223
Park, J. K., Lee, Y. J., Shin, K., Ha, Y.-J., Lee, E. Y., Song, Y. W., Choi, Y., Winthrop, K. L., & Lee, E. B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213222 · Cited by 217
Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis
Widdifield, J., Bernatsky, S., Paterson, J. M., Gunraj, N., Thorne, J. C., Pope, J., Cividino, A., & Bombardier, C. (2013) · Arthritis Care & Research · doi:10.1002/acr.21812 · Cited by 219
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
Telomerase insufficiency in rheumatoid arthritis
Fujii, H., Shao, L., Colmegna, I., Goronzy, J. J., & Weyand, C. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811332106 · Cited by 172
Park, J. K., Lee, M. A., Lee, E. Y., Song, Y. W., Choi, Y., Winthrop, K. L., & Lee, E. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211128 · Cited by 136
Rituximab-treated patients have a poor response to influenza vaccination
Eisenberg, R. A., Jawad, A. F., Boyer, J., Maurer, K., McDonald, K., Prak, E. T. L., & Sullivan, K. E. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9813-x · Cited by 126
Co-morbidity in rheumatoid arthritis
Mikuls, T. R. (2003) · Best Practice & Research Clinical Rheumatology · doi:10.1016/s1521-6942(03)00041-x · Cited by 122
Colmegna, I., Diaz‐Borjon, A., Fujii, H., Schaefer, L., Goronzy, J. J., & Weyand, C. M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23287 · Cited by 108
Fischer, L., Gerstel, P. F., Poncet, A., Siegrist, C.-A., Laffitte, E., Gabay, C., Seebach, J. D., & Ribi, C. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0663-9 · Cited by 73
“Introduction Infections cause substantial morbidity and mortality among patients with immune-mediated inflammatory disorders [1, 2].”
Background
Metadata
- Authors
- Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-09
- Volume
- 46
- Issue
- 9
- Pages
- 2287-2293
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2085947993
- Cited by
- 1,214
- References
- 18
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.